
Medicine and Health
Abiraterone acetate preferentially enriches for the gut commensal *Akkermansia muciniphila* in castrate-resistant prostate cancer patients
B. A. Daisley, R. M. Chanyi, et al.
This groundbreaking research reveals how Abiraterone acetate not only inhibits androgen biosynthesis in prostate cancer but also reshapes the gut microbiome by enriching beneficial bacteria. Conducted by a team including Brendan A. Daisley and Ryan M. Chanyi, the study highlights the potential of combining cancer therapies with targeted microbial enhancements for improved treatment outcomes.
Playback language: English
Related Publications
Explore these studies to deepen your understanding of the subject.